A biotech developing a single asset is engaged in a high-risk business, and doubly so when that asset is intended to treat Alzheimer’s disease. Today Vivoryon Therapeutics N.V. lost this gamble, disclosing the total failure of varoglutamstat in its European Phase II trial in early Alzheimer’s, VIVIAD.
Key Takeaways
- Vivoryon’s glutaminyl cyclase inhibitor varoglutamstat has failed in a European Phase II trial
All hope for Vivoryon now rests on whether a parallel US-based Phase II study, VIVA-MIND, can succeed. This has different...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?